You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

11 Results
Guidelines and Advice
May 2006
Guidelines and Advice
Guidelines and Advice
Guidelines and Advice
Status: Current
ID: GL-C50-03
Apr 2006
Guidelines and Advice
Updated
Jan 2026
Regimen
Cancer Type:
Head and Neck, 
Nasopharynx
Intent: Palliative
Feb 2026
Regimen
Intent: Palliative
Funding:
New Drug Funding Program
    Tebentafusp (Outpatient) - Unresectable or Metastatic Uveal Melanoma
High Cost Therapy Funding Program
    Tebentafusp (Inpatient) - Unresectable or Metastatic Uveal Melanoma
Mar 2026
Regimen
Cancer Type:
Hematologic, 
Multiple Myeloma
Intent: Palliative
Funding:
New Drug Funding Program
    Teclistamab (Outpatient) - Relapsed or Refractory Multiple Myeloma
High Cost Therapy Funding Program
    Teclistamab (Inpatient) - Relapsed or Refractory Multiple Myeloma
Mar 2026
Regimen
Cancer Type:
Head and Neck, 
Nasopharynx
Intent: Palliative
Updated
Apr 2026
Guidelines and Advice
Status: Current
ID: 19-4
Version: 2
Updated
Mar 2026